Table 1

Patient characteristics in the discovery cohort

IDGenderAge
(years)
EthnicityDisease duration
(years)
Clinical SELENA-SLEDAIBILAG-
2004
Anti-dsDNA
(IU/mL)*
AutoantibodiesTreatment naiveTreatment at visitDisease activity state†Biological phenotype
HCQPrednisone
(mg/kg/day)
NSAIDsDMARD/biologicals
Pt1Female15.7White1.21221380Anti-RNP, anti-SmNoYes0.12NoMycophenolate mofetilFlareHBP
Pt1Female17.6White3.20153Anti-RNP, anti-SmNoYesNoMycophenolate mofetil/belimumabLLDASMBP
Pt1Female14.5White01019548Anti-RNP, anti-SmYesNoNoNoAt diagnosisLBP
Pt2Female17.9White3121224Anti-SSA, anti-SmNoYes0.66NoMycophenolate mofetilFlareMBP
Pt2Female19White4.10033Anti-SSA, anti-SmNoYesNoMycophenolate mofetilLLDASLBP
Pt3Female9.7Mixed1.31422479NoYes0.26NoMycophenolate mofetilFlareMBP
Pt3Female12.5Mixed4.10046NoYes0.05NoMycophenolate mofetilLLDASLBP
Pt4Female18.5White2.82120.4Anti-SSA/BNoYes0.15YesMycophenolate mofetilFlareMBP
Pt4Female17.7White1.9221.5Anti-SSA/BNoYes0.08YesMycophenolate mofetil/belimumabLLDASMBP
Pt5Female17.7White3.43207.1NoYesNoMycophenolate mofetilFlareMBP
Pt5Female18White3.7003.8NoYes0.06NoMycophenolate mofetilLLDASMBP
Pt6Female15.4White3.20011Anti-RNPNoYesNoMycophenolate mofetilLLDASLBP
Pt7Female15African-American6628113Anti-RNPNoYesNoMycophenolate mofetilFlareHBP
Pt8Female15.9Mixed062232Anti-RNPNoNo0.33NoNoAt diagnosisMBP
Pt9Male18.5South-Asian3.1001.1NoYesNoMycophenolate mofetilLLDASLBP
Pt10Female5.5White0.8000.5Anti-SSANoYesNoNoLLDASLBP
Pt11Female9.8African-American01029354Anti-SSAYesNoNoNoAt diagnosisHBP
Pt12Female14.5Mixed061311Anti-SSA/B, anti-RNP, anti-SmYesNoNoNoAt diagnosisLBP
Pt13Female11.8Hispanic0421211Anti-RNP, anti-SmYesNoNoNoAt diagnosisHBP
Pt14Female14.2White0281.1Anti-RNPYesNoNoNoAt diagnosisLBP
Pt15Female16.6Asian0146433Anti-SSA/B, anti-RNP, anti-SmNoNo0.99NoNoAt diagnosisMBP
Pt16Female17.1White05132.9Anti-RNPYesNoNoNoAt diagnosisMBP
Pt17Female10.3African-American0153635Anti-SSA/BYesNoNoNoAt diagnosisHBP
  • Mixed ethnicity: pt3 (Hispanic-White), pt8 (African-American-Hispanic), pt12 (African-American-White).

  • *Measured with a fluorometric enzyme immunoassay, cut-off is 10 IU/mL.

  • †At diagnosis refers to patients sampled within 2 weeks from diagnosis.

  • BILAG, British Isles Lupus Assessment Group; DMARD, disease-modifying antirheumatic drug; HBP, high biological phenotype; HCQ, hydroxychloroquine; LBP, low biological phenotype; LLDAS, Low Lupus Disease Activity State; MBP, mixed biological phenotype; NSAIDs, non-steroidal anti-inflammatory drugs; SELENA-SLEDAI, Safety of Estrogens in Systemic Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index.